Response Genetics agrees to testing deal with MultiPlan


Response Genetics (RGDX) forges an agreement to provide its testing products to MultiPlan, a provider of healthcare cost-management products.

Response Genetics' tests help predict patients' response to cancer therapy and thereby place them on the most effective drug regimen.

Response Genetics' shares +11.7%. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs